Research & Development

Research & Development

Medical research has come a long way in the last hundred years, yet there are still many diseases for which there are no effective treatments.

That's why GlaxoSmithKline is committed to discovering and developing new medicines and vaccines. Being a large company, we can truly make a difference because we can devote vast resources to discover and develop new medicines and vaccines to improve the health of Australians. GSK has more than 20 research and development (R&D) facilities around the world, with an annual R&D budget of around $7 billion and more than 16,000 people employed in R&D. GSK's significant R&D infrastructure in Australia means that most GSK products available in Australia have also been researched here. GSK is a significant contributor to total industry spend on R&D, with investments of up to $35million each year in Australian research & development - ranking us in Australia’s top-10 R&D companies.*

*Source: Australia’s 2005 R&D and Intellectual Property Scoreboard.

GlaxoSmithKline Medicines Research Unit

The GSK Medicines Research Unit is a dedicated Clinical Pharmacology Unit situated in Sydney, Australia. The Unit contributes to the early clinical development of new medicines by conducting phase 1 and 2 clinical trials with healthy volunteers and with small patient populations.


Research Excellence Award

Our GlaxoSmithKline Australia Award for Research Excellence is one of the most prestigious awards in the Australian R&D community. It carries an $80,000 grant and has been awarded annually since 1980 in recognition of outstanding medical research.